JNJ

187.78

-1.14%↓

ABT

127.46

+1.47%↑

MDT

93.8

+0.26%↑

VEEV

292.87

-0.07%↓

A

146.15

-0.81%↓

JNJ

187.78

-1.14%↓

ABT

127.46

+1.47%↑

MDT

93.8

+0.26%↑

VEEV

292.87

-0.07%↓

A

146.15

-0.81%↓

JNJ

187.78

-1.14%↓

ABT

127.46

+1.47%↑

MDT

93.8

+0.26%↑

VEEV

292.87

-0.07%↓

A

146.15

-0.81%↓

JNJ

187.78

-1.14%↓

ABT

127.46

+1.47%↑

MDT

93.8

+0.26%↑

VEEV

292.87

-0.07%↓

A

146.15

-0.81%↓

JNJ

187.78

-1.14%↓

ABT

127.46

+1.47%↑

MDT

93.8

+0.26%↑

VEEV

292.87

-0.07%↓

A

146.15

-0.81%↓

Search

Lantheus Holdings Inc

Ouvert

SecteurSoins de santé

56.45 -0.14

Résumé

Variation du prix de l'action

24h

Actuel

Min

56.08

Max

58.23

Chiffres clés

By Trading Economics

Revenu

5.8M

79M

Ventes

5.3M

378M

P/E

Moyenne du Secteur

15.053

37.461

Marge bénéficiaire

20.832

Employés

808

EBITDA

7.7M

123M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+35.9% upside

Dividendes

By Dow Jones

Prochains Résultats

6 nov. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-1.1B

3.8B

Ouverture précédente

56.59

Clôture précédente

56.45

Sentiment de l'Actualité

By Acuity

60%

40%

316 / 373 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Lantheus Holdings Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

27 oct. 2025, 23:32 UTC

Acquisitions, Fusions, Rachats

CSL Delays Flu-Vaccine Spinoff, Cuts Guidance As U.S. Vaccination Rates Decline

27 oct. 2025, 23:00 UTC

Acquisitions, Fusions, Rachats

Australia's AUB Opens Books to EQT After Receiving $3.44 Billion Takeover Offer

27 oct. 2025, 21:42 UTC

Résultats

Waste Management 3Q Revenue Climbs, Sees Fiscal Year Revenue at Low End of Prior View

27 oct. 2025, 23:43 UTC

Market Talk

Nikkei May Rise on Easing U.S.-China Trade Tensions -- Market Talk

27 oct. 2025, 23:42 UTC

Market Talk

Gold Rises on Likely Technical Recovery -- Market Talk

27 oct. 2025, 23:37 UTC

Market Talk

Investors May Cheer CSL's Decision to Delay Seqirus Spinoff -- Market Talk

27 oct. 2025, 23:00 UTC

Résultats

The Good Vibes Are Back on Wall Street -- WSJ

27 oct. 2025, 22:45 UTC

Acquisitions, Fusions, Rachats

Australia's AUB Opens Books to EQT After Receiving $3.44B Takeover Offer

27 oct. 2025, 22:06 UTC

Market Talk
Résultats

Nucor Expects Weaker Steel Market in 4Q -- Market Talk

27 oct. 2025, 22:05 UTC

Résultats

China Southern Airlines: Continued Improvements in Business Environment Supported Results >1055.HK

27 oct. 2025, 22:04 UTC

Résultats

Cadence Reports Solid Earnings. The Stock Is Falling. -- Barrons.com

27 oct. 2025, 22:04 UTC

Résultats

China Southern Airlines 3Q Net CNY3.84B, Up 20.3% on Year >1055.HK

27 oct. 2025, 22:03 UTC

Résultats

China Southern Airlines 3Q Rev CNY51.37B, Up 3.0% on Year >1055.HK

27 oct. 2025, 21:27 UTC

Résultats

Waste Management 3Q Rev Climbs, Sees FY Rev at Low End of Prior View

27 oct. 2025, 21:19 UTC

Résultats

Cadence Reports Solid Earnings. The Stock Is Falling. -- Barrons.com

27 oct. 2025, 20:50 UTC

Market Talk
Acquisitions, Fusions, Rachats

Health Care Roundup: Market Talk

27 oct. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

27 oct. 2025, 20:37 UTC

Résultats

Waste Management: Decrease From Prior Rev Expectations Is Primarily Related to Further Decline in Recycled Commodity Pricing, Modestly Lower Rev Expectations From Healthcare Solutions >WM

27 oct. 2025, 20:37 UTC

Résultats

Waste Management: 2025 Free Cash Flow Guidance Remains Between $2.8B and $2.9B >WM

27 oct. 2025, 20:37 UTC

Résultats

Waste Management: 2025 Total Co Rev Is Now Expected Approximately $25.275B >WM

27 oct. 2025, 20:37 UTC

Résultats

Waste Management: Affirming 2025 Adjusted Operating EBITDA Guidance Between $7.475B and $7.625B >WM

27 oct. 2025, 20:31 UTC

Résultats

Nucor Sees 4Q Earnings Lower Than 3Q

27 oct. 2025, 20:30 UTC

Résultats

Nucor 3Q Steel Mills Total Shipments 6.43M Tons >NUE

27 oct. 2025, 20:30 UTC

Résultats

Nucor 3Q EPS $2.63 >NUE

27 oct. 2025, 20:30 UTC

Résultats

Nucor 3Q Net $607M >NUE

27 oct. 2025, 20:30 UTC

Résultats

Nucor 3Q Sales $8.52B >NUE

27 oct. 2025, 20:30 UTC

Résultats

Nucor 3Q Total Tons Shipped to Outside Customers Down 1% >NUE

27 oct. 2025, 20:30 UTC

Résultats

Waste Management 3Q Adj EPS $1.98 >WM

27 oct. 2025, 20:30 UTC

Résultats

Waste Management 3Q Rev $6.44B >WM

27 oct. 2025, 20:30 UTC

Résultats

Waste Management 3Q Net $603M >WM

Comparaison

Variation de prix

Lantheus Holdings Inc prévision

Objectif de Prix

By TipRanks

35.9% hausse

Prévisions sur 12 Mois

Moyen 79 USD  35.9%

Haut 99 USD

Bas 70 USD

Basé sur 9 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

9 ratings

6

Achat

3

Maintien

0

Vente

Score Technique

By Trading Central

79.24 / 103.64Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Weak Bullish Evidence

Long Terme

Neutral Evidence

Sentiment

By Acuity

316 / 373Classement par Soins de santé

Sentiment de l'Actualité

Indications Baissières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Lantheus Holdings Inc

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.
help-icon Live chat